Erythropoietin Use in Therapy of Anemia Associated with Bone Marrow Transplantation in Children
Erythropoietin (EPO) is a hematopoietic growth factor that plays a vital role in erythropoiesis regulating the red blood cell synthesis. EPO is a hormone-like glycoprotein (molecular weight 24 000 daltons) that regulates the red blood cell synthesis and the proliferation and maturation of erythroid cells in bone marrow . Its concentration is related to the degree of anemic hypoxia. Recombinant DNA technology has permitted the production of sufficient amounts of recombinant human EPO (rhEPO) for clinical application . Endogenous EPO production becomes inadequate in most recipients of megachemotherapy and bone marrow transplantation 2–3 weeks after transplantation. During this time, erythrocyte transfusions are required . Recombinant EPO, which was first successfully applied in anemic patients with chronic renal failure, is increasingly being used to treat chronic anemia in cancer and patients after BMT [4,7,9,10,11,15].
KeywordsBone Marrow Transplantation Autologous Bone Marrow Transplantation Hematopoietic Growth Factor Chronic Anemia Recombinant Erythropoietin
Unable to display preview. Download preview PDF.
- 3.Miller CB. Erythropoietin in high-dose chemotherapy. In: J. Armitage, K. Antman (eds), High-dose Cancer Therapy, Pharmacology, Hematopoietins, Stem cells, 1st Edition, Wilkins and Wilkins, Maryland PP385–401, 1992Google Scholar
- 4.Link H, Diedrich H, Ebell W, et al. Recombinant human erythropoietin after allogenic bone marrow transplantation. Bone marrow transplantation 1990; Suppl. 2: 219aGoogle Scholar
- 6.Kuratowska Z. Erythropoietin use in hematological patients. Acta Hematol. Polon. 1997, 28 suppl. 2 73–82Google Scholar
- 7.Dornbusch P., Clinical efficacy of r-HuEPO in the treatment of cancer-related anemia in pediatric patients, Erythropoiesis. 1996, 1Google Scholar
- 8.Backs B, Broeders L., Hoefslood D, et al. Erythropoieis in myelodysplastic syndrome: expression of receptor for erythropoietin and kit-ligand. Leukemia 1996, 3, 396–401.Google Scholar
- 9.Sevelda P, Kurtz Ch., Marth Ch., Prospective randomized placebo controlled trial of erythropoietin (erypo) in patients with chronic anemia and gynecological cancer. Por Am Assoc Clin Oncol 1996, 15, 287Google Scholar
- 12.Hellstrom-Lindengerg E., Efficacy of erythroprotein in myelodysplastic syndromes; a meta analysis of 205 patients from 17 studies. Brit. J Hematol, 1995, 44, 229–236.Google Scholar
- 13.Rose E., Rai K., Revicki D, Brown R., Reblando J., Clinical and health staus assesments in anemic chronic lymphocytic (CLL) patients treated with epoietin alfa (EPO) Blood, 1994, 84, 52Google Scholar
- 14.Podsakoff G. M, Paszty M, Narla M et al. Improvement of anemia of murine beta talasemia following administration of the erythropoietin gene. Acta Hematol. 1997, S1, 98, 10, 3Google Scholar
- 16.Ayash L, Elias A., et al. Recombinant human erythropoietin (EPO) in anemia associated with autologous bone marrow transplantation (ABMT) Blood 1990, 76 suppl. 1, 131 a.Google Scholar
- 17.Zecca M., Erythropoietin treatment in pediatrics. Oncology Reviev, 1992, 7, 518Google Scholar
- 18.Remaggi G., Milone G., Fernandez I., Martinez Rolon J., Desmery P., Pavlovsky S., Evaluation oh human recombinant erythropoietin use in autologus peripheral progenitor cell transplant. Blood vol. 90, No 10, Suppl. 2, 362b.Google Scholar